Developer docs
API playgroundTry for free, no card

Search company profiles

Arkin Capital

Full company profile

uuid003vnii

Namestring
Arkin Capital
Legal namestring
M. Arkin (1999) Ltd.
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Arkin Capital (legal entity M. Arkin (1999) Ltd.) is an Israeli private multi-asset investment manager founded in 2009 by Mori Arkin and headquartered in Herzliya. The firm manages over $2 billion in assets under management across four specialized investment arms: Arkin Health (life-sciences VC via Arkin Bio, healthcare hedge funds via Sphera Health, and digital-health VC via A-Squared Ventures), Arkin Equity (Israeli public markets via the Idea Hedge Fund, private equity via Arkin Private Equity, and venture-building via Arkin Foundry), Arkin Tech (early-stage diversified technology), and Arkin Real Estate (North American and European residential, commercial, and industrial properties). The firm invests across the full capital stack from seed and Series A (Arkin Bio Ventures, Arkin Tech, Arkin Foundry) through growth and late-stage (Arkin Bio Capital, Arkin Opportunity) and into public equities and hedge fund strategies, with named portfolio companies including DigitalOcean, Cellebrite, Keros Therapeutics, HI-Bio, Crossbow Therapeutics, Nocion Therapeutics, TopGum, and Fu-Gen.

Arkin generates revenue through three primary streams: (i) annual management fees, typically ~2% on committed/invested capital across its closed-end fund vehicles, providing a recurring base; (ii) performance fees / carried interest, typically ~20% above hurdle rates, earned on exits such as the HI-Bio acquisition by Biogen for up to $1.8 billion; and (iii) direct investment returns on proprietary capital co-invested alongside fund capital. The firm is privately held by the Arkin family (Mori Arkin as Founder & Chairman, Nir Arkin as CEO), with institutional backing from named Israeli insurance and pension LPs (Menora, Harel, Phoenix, Migdal, Clal, Leumi, Yalin Lapidot, Meitav, and others), and operates with a lean team of approximately 20 employees including six Managing Partners and principals with PhD-level scientific training. The most recent strategic step was the January 2026 close of a $100 million third early-stage biotech fund, alongside parallel 2025 launches of A-Squared Ventures (digital health) and the IDEA Bond Hedge Fund.

Short descriptiontext

Arkin Capital is a Herzliya-based private multi-asset manager founded in 2009 by Mori Arkin, managing over $2 billion across life-sciences VC, healthcare hedge funds, Israeli equities, early-stage tech, and global real estate for Israeli institutional LPs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHerzliya, Israel
HQ citystring
Herzliya
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital management, private equity funds, hedge fund management, asset management services, life sciences investment
Industry4 codes
1Venture Capital Fund-of-Funds / Multi-Manager Platforms
CodeFSANAAAJPrimaryYes
2Advisory Portfolio Management (Non-Discretionary)
CodeFSAAABADPrimaryNo
3Corporate Strategic Real Assets & Infrastructure Venture Investing
CodeFSANAHANPrimaryNo
4Portfolio Construction & Asset Allocation Advisory
CodeFSAEAAACPrimaryNo
NAICS code4 codes
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
  • Other Investment Pools and Funds5259
  • Funds, Trusts, and Other Financial Vehicles525
SIC code3 codes
  • Investment Advice6282
  • Investors, Nec6799
  • Real Estate Dealers (For Their Own Account)6532
Product category
Multi-Asset Investment Management
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Management Fees
TypeSubscription Recurring
Description

Annual management fees charged on assets under management as a percentage of committed capital, typical for VC/PE fund structures. Provides steady recurring revenue base.

2Performance Fees (Carried Interest)
TypeTransaction Fee
Description

Carried interest earned on investment returns above hurdle rates, typically 20% of profits. Represents the primary value creation incentive for fund managers.

3Investment Returns
TypeTransaction Fee
Description

Direct returns on proprietary capital investments alongside managed fund capital. Returns realized through exits via IPOs, acquisitions, and secondary transactions.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Management fees on committed capital (typically ~2% annually)
ModelSubscriptionBilling cadenceAnnual
Notes

Standard VC/PE management fee structure - annual fee on committed/invested capital. Performance-based carried interest (typically 20%) charged on returns above the hurdle rate.

GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1Arkin Bio Ventures
Description

Early-stage biotech venture fund focusing on pre-clinical and clinical-stage biotech companies

arkin-capital.com
+4 more records
Core offering1 text field

Arkin Capital is a multi-asset investment manager managing over $2 billion across venture capital, private equity, and hedge fund strategies. The firm operates four main investment arms — Arkin Health (biotech and healthcare), Arkin Equity (private equity and Israeli public markets), Arkin Tech (early-stage technology), and Arkin Real Estate — providing institutional investors with access to specialized fund vehicles.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • $100M raised for third biotech fund demonstrating LP confidence
+1 more record
Product overview1 text field

Arkin Capital is a multi-asset investment manager with over $2 billion under management across four main investment arms. Arkin Health includes Arkin Bio (life sciences VC), Sphera Health (healthcare hedge funds), and A-Squared Ventures (digital health). Arkin Equity encompasses the Idea Hedge Fund (Israeli equities), Arkin Private Equity, and Arkin Foundry. Arkin Tech invests in diversified technology early-stage companies, while Arkin Real Estate manages investments across global real estate markets. The company was established in 2009 by Mori Arkin and supports portfolio companies from early to late stages.

Product and service8 records
1Arkin Bio
CategoryVenture Capital Fund
Description

A leading global life sciences VC offering early-stage biotech investments through Arkin Bio Ventures and late-stage biotech investments through Arkin Bio Capital, for institutional investors seeking biotech exposure.

2Sphera Health
CategoryHedge Fund
Description

Israel's first and leading healthcare hedge fund, partnering with Sphera Funds Management. Includes Sphera Global Healthcare (long/short equity strategy) and Sphera Biotech (focused on small and mid-cap biotech companies), for investors seeking healthcare-focused hedge fund returns.

3A-Squared Ventures
CategoryVenture Capital Fund
Description

Digital health investment vehicle within Arkin Health, focusing on digital health startups alongside Arkin Bio's life sciences portfolio.

4Idea Hedge Fund
CategoryHedge Fund
Description

Hedge fund focused on small and medium-sized Israeli and Israeli-related companies employing a long-bias strategy using fundamental analysis to identify underpriced stocks and debt.

5Arkin Private Equity
CategoryPrivate Equity Fund
Description

Since 2019, invests in high-growth companies in partnership with leading capital market players. Focuses on building value through strategic and long-term investments in companies such as TopGum, EverPhone, and Cellebrite.

6Arkin Foundry
CategoryVenture Capital / Venture Building Fund
Description

Transforms innovative ideas into successful companies by leveraging deep industry knowledge and network. Focuses on opportunities particularly within Israel, supporting ventures from seeding to anchoring stage.

7Arkin Tech
CategoryVenture Capital Fund
Description

Invests in diversified technologies, partnering primarily with visionary early-stage companies. Has made over 30 investments including DigitalOcean, Lendbuzz, HoneyBook, Via, and Percepto.

8Arkin Real Estate
CategoryReal Estate Fund
Description

Leading investor in global real estate opportunities, active across North America and Europe via various vehicles and investment strategies in residential, commercial, and industrial markets.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Arkin Capital partnered with Fu-Gen, a Nordic renewable energy developer, for renewable energy project development. The partnership focuses on developing utility-scale solar and wind projects in the Nordic region. Fu-Gen has developed over 215 MW of operational renewable energy capacity with an additional 9 GW in development pipeline. The collaboration represents a strategic expansion of Arkin's renewable energy investment activities into European markets.

Recent move17 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Israel-focused early-stage venture firm led by former Yahoo and AOL executives. Comparable as an Israeli VC with strong ecosystem relationships and early-stage focus.

TypeDirect peer
Description

Israel-based VC firm with multiple funds spanning early-stage to growth-stage investments across deep tech, cybersecurity, and digital health. Comparable in Israeli ecosystem focus and multi-fund platform structure.

TypeDirect peer
Description

Israel-based healthcare-dedicated venture capital firm with multiple funds covering therapeutics, medical devices, and digital health. Direct competitor in the Israeli biotech VC space.

TypeBroad incumbent
Description

Global multi-stage venture and growth capital firm with broad sector exposure. Comparable as a multi-strategy asset manager but operates at much larger scale across global geographies.

TypeDirect peer
Description

Israeli holding and venture capital firm focused on technology and healthcare investments. Comparable as an Israeli multi-fund platform with similar mix of early-stage tech and biotech holdings.

TypeDirect peer
Description

Israel-based healthcare private equity firm focused on medical devices and healthtech. Comparable as an Israeli-domiciled healthcare-focused investment manager with multi-fund structure.

TypeDirect peer
Description

Israel's largest venture capital firm managing multiple funds across tech, healthcare, and growth stages. Directly comparable as an Israeli multi-stage, multi-sector asset manager with similar institutional LP backing.

TypeDirect peer
Description

Israeli healthtech and biotech venture fund with both growth and early-stage vehicles. Comparable as a specialized Israeli healthcare-focused VC platform with institutional backing.

TypeBroad incumbent
Description

Global growth equity firm investing across sectors and stages. Comparable as a multi-strategy growth investor, though focused on larger checks and broader geographic footprint.

TypeDirect peer
Description

Israel-based global venture investment platform with multiple sector-focused funds including healthcare. Comparable as a multi-asset Israeli investment manager with similar LP base among Israeli institutional and individual investors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries8 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment5 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arkin Capital

Multi-Asset Investment Managementarkin-capital.com

Arkin Capital is a Herzliya-based private multi-asset manager founded in 2009 by Mori Arkin, managing over $2 billion across life-sciences VC, healthcare hedge funds, Israeli equities, early-stage tech, and global real estate for Israeli institutional LPs.

What Arkin Capital does

Arkin Capital (legal entity M. Arkin (1999) Ltd.) is an Israeli private multi-asset investment manager founded in 2009 by Mori Arkin and headquartered in Herzliya. The firm manages over $2 billion in assets under management across four specialized investment arms: Arkin Health (life-sciences VC via Arkin Bio, healthcare hedge funds via Sphera Health, and digital-health VC via A-Squared Ventures), Arkin Equity (Israeli public markets via the Idea Hedge Fund, private equity via Arkin Private Equity, and venture-building via Arkin Foundry), Arkin Tech (early-stage diversified technology), and Arkin Real Estate (North American and European residential, commercial, and industrial properties). The firm invests across the full capital stack from seed and Series A (Arkin Bio Ventures, Arkin Tech, Arkin Foundry) through growth and late-stage (Arkin Bio Capital, Arkin Opportunity) and into public equities and hedge fund strategies, with named portfolio companies including DigitalOcean, Cellebrite, Keros Therapeutics, HI-Bio, Crossbow Therapeutics, Nocion Therapeutics, TopGum, and Fu-Gen.

Arkin generates revenue through three primary streams: (i) annual management fees, typically ~2% on committed/invested capital across its closed-end fund vehicles, providing a recurring base; (ii) performance fees / carried interest, typically ~20% above hurdle rates, earned on exits such as the HI-Bio acquisition by Biogen for up to $1.8 billion; and (iii) direct investment returns on proprietary capital co-invested alongside fund capital. The firm is privately held by the Arkin family (Mori Arkin as Founder & Chairman, Nir Arkin as CEO), with institutional backing from named Israeli insurance and pension LPs (Menora, Harel, Phoenix, Migdal, Clal, Leumi, Yalin Lapidot, Meitav, and others), and operates with a lean team of approximately 20 employees including six Managing Partners and principals with PhD-level scientific training. The most recent strategic step was the January 2026 close of a $100 million third early-stage biotech fund, alongside parallel 2025 launches of A-Squared Ventures (digital health) and the IDEA Bond Hedge Fund.

Arkin Capital firmographics

Firmographics
Name
Arkin Capital
Legal name
M. Arkin (1999) Ltd.
Website
https://arkin-capital.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Arkin Capital is a Herzliya-based private multi-asset manager founded in 2009 by Mori Arkin, managing over $2 billion across life-sciences VC, healthcare hedge funds, Israeli equities, early-stage tech, and global real estate for Israeli institutional LPs.
Ownership category
akta.pro rank

Arkin Capital industry classification

Industry
Product category
Multi-Asset Investment Management
NAICS
Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Other Investment Pools and Funds (5259), Funds, Trusts, and Other Financial Vehicles (525)
SIC
Investment Advice (6282), Investors, Nec (6799), Real Estate Dealers (For Their Own Account) (6532)
akta.pro primary industry
Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)
akta.pro secondary industries
Advisory Portfolio Management (Non-Discretionary) (FSAAABAD), Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN), Portfolio Construction & Asset Allocation Advisory (FSAEAAAC)

Keywords

  • Venture capital management
  • Private equity funds
  • Hedge fund management
  • Asset management services
  • Life sciences investment

Where Arkin Capital is headquartered

Location

Headquarters

HQ city
Herzliya
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Arkin Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Management Fees: Annual management fees charged on assets under management as a percentage of committed capital, typical for VC/PE fund structures. Provides steady recurring revenue base.
  2. Performance Fees (Carried Interest): Carried interest earned on investment returns above hurdle rates, typically 20% of profits. Represents the primary value creation incentive for fund managers.
  3. Investment Returns: Direct returns on proprietary capital investments alongside managed fund capital. Returns realized through exits via IPOs, acquisitions, and secondary transactions.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualManagement fees on committed capital (typically ~2% annually)

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Arkin Capital product offering

Product offering

Core offering

Arkin Capital is a multi-asset investment manager managing over $2 billion across venture capital, private equity, and hedge fund strategies. The firm operates four main investment arms — Arkin Health (biotech and healthcare), Arkin Equity (private equity and Israeli public markets), Arkin Tech (early-stage technology), and Arkin Real Estate — providing institutional investors with access to specialized fund vehicles.

Product overview

Arkin Capital is a multi-asset investment manager with over $2 billion under management across four main investment arms. Arkin Health includes Arkin Bio (life sciences VC), Sphera Health (healthcare hedge funds), and A-Squared Ventures (digital health). Arkin Equity encompasses the Idea Hedge Fund (Israeli equities), Arkin Private Equity, and Arkin Foundry. Arkin Tech invests in diversified technology early-stage companies, while Arkin Real Estate manages investments across global real estate markets. The company was established in 2009 by Mori Arkin and supports portfolio companies from early to late stages.

Differentiator

Problem solved

Functional benefit

Brands

  • Arkin Bio Ventures: Early-stage biotech venture fund focusing on pre-clinical and clinical-stage biotech companies
  • Arkin Bio Capital
  • Sphera Global Healthcare
  • Sphera Biotech
  • Idea Hedge Fund

Products and services

  • Arkin Bio A leading global life sciences VC offering early-stage biotech investments through Arkin Bio Ventures and late-stage biotech investments through Arkin Bio Capital, for institutional investors seeking biotech exposure.
  • Sphera Health Israel's first and leading healthcare hedge fund, partnering with Sphera Funds Management. Includes Sphera Global Healthcare (long/short equity strategy) and Sphera Biotech (focused on small and mid-cap biotech companies), for investors seeking healthcare-focused hedge fund returns.
  • A-Squared Ventures Digital health investment vehicle within Arkin Health, focusing on digital health startups alongside Arkin Bio's life sciences portfolio.
  • Idea Hedge Fund Hedge fund focused on small and medium-sized Israeli and Israeli-related companies employing a long-bias strategy using fundamental analysis to identify underpriced stocks and debt.
  • Arkin Private Equity Since 2019, invests in high-growth companies in partnership with leading capital market players. Focuses on building value through strategic and long-term investments in companies such as TopGum, EverPhone, and Cellebrite.
  • Arkin Foundry Transforms innovative ideas into successful companies by leveraging deep industry knowledge and network. Focuses on opportunities particularly within Israel, supporting ventures from seeding to anchoring stage.
  • Arkin Tech Invests in diversified technologies, partnering primarily with visionary early-stage companies. Has made over 30 investments including DigitalOcean, Lendbuzz, HoneyBook, Via, and Percepto.
  • Arkin Real Estate Leading investor in global real estate opportunities, active across North America and Europe via various vehicles and investment strategies in residential, commercial, and industrial markets.

Quantifiable outcome

  • $100M raised for third biotech fund demonstrating LP confidence
  • +1 more outcomes

Companies that use Arkin Capital

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Arkin Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Arkin Capital partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Fu-GencoreStrategic or Co-development Partner · 1 January 2024Arkin Capital partnered with Fu-Gen, a Nordic renewable energy developer, for renewable energy project development. The partnership focuses on developing utility-scale solar and wind projects in the Nordic region. Fu-Gen has developed over 215 MW of operational renewable energy capacity with an additional 9 GW in development pipeline. The collaboration represents a strategic expansion of Arkin's renewable energy investment activities into European markets.

Scale indicators5 records

Recent moves17 records

Expansion highlights5 records

Arkin Capital competitors and assessment

Company assessment

Direct peers

  • TLV Partners: Israel-focused early-stage venture firm led by former Yahoo and AOL executives. Comparable as an Israeli VC with strong ecosystem relationships and early-stage focus.
  • Jerusalem Venture Partners (JVP): Israel-based VC firm with multiple funds spanning early-stage to growth-stage investments across deep tech, cybersecurity, and digital health. Comparable in Israeli ecosystem focus and multi-fund platform structure.
  • Pontifax: Israel-based healthcare-dedicated venture capital firm with multiple funds covering therapeutics, medical devices, and digital health. Direct competitor in the Israeli biotech VC space.
  • Elron Electronic Industries: Israeli holding and venture capital firm focused on technology and healthcare investments. Comparable as an Israeli multi-fund platform with similar mix of early-stage tech and biotech holdings.
  • Accelmed: Israel-based healthcare private equity firm focused on medical devices and healthtech. Comparable as an Israeli-domiciled healthcare-focused investment manager with multi-fund structure.
  • Pitango Venture Capital: Israel's largest venture capital firm managing multiple funds across tech, healthcare, and growth stages. Directly comparable as an Israeli multi-stage, multi-sector asset manager with similar institutional LP backing.
  • aMoon Fund: Israeli healthtech and biotech venture fund with both growth and early-stage vehicles. Comparable as a specialized Israeli healthcare-focused VC platform with institutional backing.
  • OurCrowd: Israel-based global venture investment platform with multiple sector-focused funds including healthcare. Comparable as a multi-asset Israeli investment manager with similar LP base among Israeli institutional and individual investors.

Broad incumbents

  • Sequoia Capital: Global multi-stage venture and growth capital firm with broad sector exposure. Comparable as a multi-strategy asset manager but operates at much larger scale across global geographies.
  • General Atlantic: Global growth equity firm investing across sectors and stages. Comparable as a multi-strategy growth investor, though focused on larger checks and broader geographic footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Arkin Capital social profiles

Digital presence

Arkin Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arkin Capital leadership team

Management profile

Number of profiles

Profiles21 records

Arkin Capital subsidiaries and ownership

Company hierarchy

Subsidiaries8 records

Arkin Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arkin Capital M&A and investment

M&A and investment

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arkin Capital

What does Arkin Capital do?

Arkin Capital is a multi-asset investment manager managing over $2 billion across venture capital, private equity, and hedge fund strategies. The firm operates four main investment arms — Arkin Health (biotech and healthcare), Arkin Equity (private equity and Israeli public markets), Arkin Tech (early-stage technology), and Arkin Real Estate — providing institutional investors with access to specialized fund vehicles.

Is Arkin Capital a public or private company?

Arkin Capital is a private company. It is classified as family owned and is currently operating.

When was Arkin Capital founded?

Arkin Capital was founded in 2009. It employs 11 to 50 people.

Where is Arkin Capital based?

Arkin Capital is headquartered in Herzliya, Israel, in the Middle East region.

How does Arkin Capital make money?

Three revenue lines are on record. Management Fees are the primary driver. The others are performance Fees (Carried Interest) and investment Returns.

Who are Arkin Capital's main competitors?

Direct peers on record are TLV Partners, Jerusalem Venture Partners (JVP), Pontifax, Elron Electronic Industries, Accelmed, Pitango Venture Capital, aMoon Fund and OurCrowd. Broad incumbents are Sequoia Capital and General Atlantic.

Does Arkin Capital have an API?

No public API is recorded for Arkin Capital.

What industry is Arkin Capital in?

Arkin Capital's product category is Multi-Asset Investment Management. Its primary akta.pro industry code is FSANAAAJ, Venture Capital Fund-of-Funds / Multi-Manager Platforms, with a secondary code of FSAAABAD, Advisory Portfolio Management (Non-Discretionary). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Jerusalem PostIsraeli plant-based protein co Plantopia raises $9mIsraeli startup Plantopia has completed a $9 million financing round led by US dairy giant Schreiber Foods, with participation from Siddhi Capital and local investors including Yotvata, Arkin Capital, and the foodtech incubator Fresh Start. The funds will enable the company to advance to industrial production at a manufacturing plant under construction on Kibbutz Sdot Yam, bringing its total raised to date to over $16 million. Plantopia has developed a platform for producing animal proteins, including complete casein with all four components, through advanced biomolecular agriculture using indoor vertical farming.GlobesIsraeli plant-based protein co Plantopia raises $9mIsraeli startup Plantopia has completed a $9 million financing round led by US dairy giant Schreiber Foods, with participation from Siddhi Capital, Yotvata, Arkin Capital, and the Fresh Start foodtech incubator, bringing its total raised to over $16 million. The funds will enable the company to advance to industrial production at a manufacturing plant under construction on Kibbutz Sdot Yam, implementing technology developed over eight years to produce plant-based proteins identical to cow's milk casein. Plantopia claims to be the first and only company in the world to have produced complete casein with all four components, representing what the CEO called 'the Holy Grail of the cheese world.'Venture Capital Access OnlineBionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory DiseasesBionyra Pharma announced its launch with a $165 million oversubscribed Series A co-led by Jeito Capital and Sofinnova Partners. The company is advancing next-generation biologics for immune-mediated inflammatory diseases, including atopic dermatitis and IBD, with a pipeline of clinical and IND-stage antibodies.BioSpaceBionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory DiseasesBionyra Pharma announced its launch with a $165 million oversubscribed Series A co-led by Jeito Capital and Sofinnova Partners. The company is advancing next-generation biologics for atopic dermatitis and inflammatory bowel disease, including a Phase 1 study for BYN-003. The round was oversubscribed, with participation from Arkin Bio, Sanofi Ventures, and others.The Jerusalem PostShifters: Robots on the frontlineIsraeli deep-tech start-up Shifters, which develops AI-native autonomous ground robotic teams, has raised $10.2 million in seed funding led by Ace Capital Partners, with participation from Aurelius Capital Management, Corner Ventures, Arkin Capital, and Fresh Fund, bringing its total funding to $15 million. The company, founded in 2023 and headquartered in Washington with R&D operations in Israel, is developing supervised autonomous ground robotics intended to enter high-risk and contested environments before troops do. The funding will be used to expand agentic AI capabilities, accelerate manufacturing readiness, and grow the company's presence in the US, Middle East, and Europe.FinSMEsShifters Raises $10.2M in Seed FundingShifters, a Washington, DC-based AI-native autonomous robotic teams company, raised $10.2M in seed funding led by Ace Capital Partners. The round brings total funding to $15M, which the company will use to expand operations and development. The platform targets defense, security, and commercial operations.Venture Capital Access OnlineShifters Raises $10.2 Million Seed Round Led by Ace Capital Partners to Advance AI-Native Ground RoboticsShifters announced a $10.2 million seed round led by Ace Capital Partners, bringing total funding to $15 million. The funds will support AI development, manufacturing readiness, and global expansion for its AI-native ground robotic systems. The company aims to deploy these systems in defense, security, and commercial applications.VC News DailyShifters Raises $10.2 Million Seed RoundShifters, a global technology company building AI-native autonomous robotic teams, raised $10.2 million in seed funding led by Ace Capital Partners. The round brings its total funding to $15 million, with participating investors including Aurelius Capital Management, Corner Ventures, Arkin Capital, STEP World, and Fresh Fund.FierceBiotechCrossbow hits $77M series B round to bankroll quiver of T-BoltsCrossbow Therapeutics has secured a $77 million Series B funding round co-led by Taiho Ventures and Arkin Bio Capital, with participation from returning investors Eli Lilly and Pfizer Ventures, to fund clinical trials of its T-cell engager pipeline including lead asset CBX-250. The biotech will advance its ongoing Phase 1 trial in acute myeloid leukemia and other myeloid malignancies with a data readout expected at the end of 2026, while also preparing a second TCE candidate (CBX-663) for hematologic and solid tumor trials scheduled to begin in Q3. The company, incubated at MPM BioImpact and launched in 2023 with an $80 million Series A, is led by former AstraZeneca chief medical officer Briggs Morrison.CrossbowtxMarch 18, 2026Crossbow Therapeutics has raised $77 million in Series B financing co-led by Taiho Ventures and Arkin Bio Capital to advance its T-Bolt™ TCR-mimetic antibody therapies for cancer treatment. The funding will support completion of the CROSSCHECK-001 Phase 1 trial of lead program CBX-250 in myeloid malignancies and enable submission of an IND application for CBX-663 to treat hematologic and solid tumors, with initial clinical data expected around the end of 2026.